Chemotherapy versus best supportive care in stage IV non-small cell lung cancer, non metastatic to the brain
Rev. Hosp. Clin. Fac. Med. Univ. Säo Paulo
;
56(2): 53-58, Mar.-Apr. 2001. graf, tab
Artículo
en Inglés
| LILACS
| ID: lil-288651
ABSTRACT
Stage IV non-small cell lung cancer is a fatal disease, with a median survival of 14 months. Systemic chemotherapy is the most common approach. However the impact in overall survival and quality of life still a controversy. OBJECTIVES:
To determine differences in overall survival and quality of life among patients with stage IV non-small cell lung cancer non-metastatic to the brain treated with best supportive care versus systemic chemotherapy. PATIENTS From February 1990 through December 1995, 78 eligible patients were admitted with the diagnosis of stage IV non-small cell lung cancer . Patients were divided in 2 groups Group A (n=31 -- treated with best supportive care ), and Group B (n=47 -- treated with systemic chemotherapy).RESULTS:
The median survival time was 23 weeks (range 5 -- 153 weeks) in Group A and 55 weeks (range 7.4 -- 213 weeks) in Group B (p=0.0018). In both groups, the incidence of admission for IV antibiotics and need of blood transfusions were similar. Patients receiving systemic chemotherapy were also stratified into those receiving mytomycin, vinblastin, and cisplatinum, n=25 and those receiving other combination regimens (platinum derivatives associated with other drugs, n=22). Patients receiving mytomycin, vinblastin, and cisplatinum, n=25 had a higher incidence of febrile neutropenia and had their cycles delayed for longer periods of time than the other group. These patients also had a shorter median survival time (51 versus 66 weeks, p=0.005).CONCLUSION:
In patients with stage IV non-small cell lung cancer, non-metastatic to the brain, chemotherapy significantly increases survival compared with best supportive care
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Cuidados Paliativos
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Carcinoma de Pulmón de Células no Pequeñas
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
/
Factores de riesgo
Límite:
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Rev. Hosp. Clin. Fac. Med. Univ. Säo Paulo
Asunto de la revista:
Medicina
Año:
2001
Tipo del documento:
Artículo
País de afiliación:
Brasil
Institución/País de afiliación:
Fundaçäo Antônio Prudente/BR
Similares
MEDLINE
...
LILACS
LIS